Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 7637-7637
Author(s):  
N. R. Foster ◽  
Y. Qi ◽  
Q. Shi ◽  
J. E. Krook ◽  
J. W. Kugler ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Tumor Response ◽  
Progression Free Survival ◽  
Small Cell ◽  
Surrogate Endpoints ◽  
Small Cell Lung ◽  
North Central ◽  
Free Survival ◽  
Extensive Stage

scholarly journals Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer

Cancer ◽  
2010 ◽  
Vol 117 (6) ◽  
pp. 1262-1271 ◽  
Author(s):  
Nathan R. Foster ◽  
Yingwei Qi ◽  
Qian Shi ◽  
James E. Krook ◽  
John W. Kugler ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Tumor Response ◽  
Progression Free Survival ◽  
Small Cell ◽  
Surrogate Endpoints ◽  
Small Cell Lung ◽  
Free Survival ◽  
Extensive Stage

Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review

Immunotherapy ◽  
2021 ◽  
Author(s):  
Xingyu Liu ◽  
Huifang Xing ◽  
Hongbing Zhang ◽  
Hongyu Liu ◽  
Jun Chen
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Progression Free Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
Standard Chemotherapy ◽  
Free Survival ◽  
Extensive Stage

Aim: We conducted a systematic review and network meta-analysis to evaluate the efficacy of immunotherapy versus chemotherapy to treat extensive-stage small-cell lung cancer. Methods: We analyzed several eligible clinical trials using fixed or random-effects models to evaluate relative treatment effects depending on heterogeneity. Results: In the experimental group, immunotherapy showed significant improvement in overall survival (hazard ratio [HR]: 0.82; 95% CI: 0.74–0.89; I2 = 31.4%; p < 0.001) and progression-free survival (HR: 0.77; 95% CI: 0.80–0.83; I2 = 22.7%; p < 0.001). Conclusion: Immunotherapy is likely to significantly improve extensive-stage small-cell lung cancer patients' overall survival and progression-free survival compared with standard chemotherapy. Anti-PD L1 exhibited superior overall survival compared with anti-PD 1 and anti-CTLA4.

Sign in / Sign up

Export Citation Format

Share Document